Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Lung Neoplasms 5Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Neoplasms 4Colorectal Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Breast Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Urothelial Cancer 1Urinary Bladder Diseases 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Testicular Neoplasms 1

Interventions

Sorafenib 3vandetanib 2alectinib 2Sodium 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Bevacizumab 2tremelimumab 1temsirolimus 1ponatinib 1perflutren 1pembrolizumab 1methyl N-acetylsibirosaminide 1lenvatinib 1gallium 68 PSMA-11 1fosbretabulin 1durvalumab 1combretastatin 1cobimetinib 1cabozantinib 1X-Rays 1Valproic Acid 1Thyroxine 1Technetium Tc 99m Sestamibi 1Sirolimus 1Radiofrequency Ablation 1Presenilin-1 1Paclitaxel 1PLX8394 1Lubricant Eye Drops 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Thyroid Neoplasms × durvalumab × Clear all
NCT03753919 2026-03-11

DUTHY

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Terminated
79 enrolled 25 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡